source
- Lilly ends partnership with Foghorn after lead cancer drug fails efficacy testsLilly announced it is ending its collaboration with Foghorn Therapeutics after the biotech's lead cancer candidate, FHD-909, did not meet efficacy benchmarks in testing. The decision halts the join…
- HHS launches funding programs to accelerate U.S. clinical trials amid rising Chinese competitionHHS announced new initiatives aimed at speeding up clinical trial development in the United States. The department introduced a five-year program called "Surpass" that seeks proposals from teams wi…